![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » IVAX TO CHALLENGE PATENTS PROTECTING ASTRAZENECA'S PULMICORT RESPULES
IVAX TO CHALLENGE PATENTS PROTECTING ASTRAZENECA'S PULMICORT RESPULES
October 31, 2005
IVAX said it filed its Abbreviated New Drug Application (ANDA) for budesonide inhalation suspension with the US Food and Drug Administration in late 2004. It amended its ANDA in September 2005, alleging invalidity and non-infringement in respect of certain of AstraZeneca's patents.
Forbes (http://www.forbes.com/business/feeds/afx/2005/10/31/afx2308215.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct